NCT01852942View on ClinicalTrials.gov

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
HIV InfectionHIV Infections
Interventions
DRUG

Losartan

Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.

DRUG

Placebo

one tablet by mouth daily

Trial Locations (1)

55455

University of Minnesota, Division of Infectious Diseases, Minneapolis

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Minnesota

OTHER

NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV | Biotech Hunter | Biotech Hunter